Kinimmune in the News
Kinimmune publishes results from a Phase I “Window of Opportunity” trial in patients with solid tumors
March 3rd, 2023
Kinimmune is developing tissue adhesive formulations that persist in treated tumors to limit systemic exposure and maximize the therapeutic window.
Read More
Kinimmune wins highly competitive NCI funding to advance solid tumor immunotherapy for patients refractory to checkpoint inhibitors
November 9th, 2022
Kinimmune is developing KIN-102, a first-in-class immunostimulant that persists in treated tumors to minimize systemic side effects.